Abbott

Sema4 said it will provide SARS-CoV-2 viral and antibody testing to Connecticut residents including state employees and first responders.

More than 70 percent of labs surveyed experienced supply chain interruptions, forcing them to validate three or more diagnostic testing methods.

The approval was based on data showing superior efficacy for Alunbrig compared to Pfizer's Xalkori, especially in patients with brain metastasis.

A UK official said that the government is working with other companies on developing tests with rapid turnaround times and noted a test from UK firm OptiGene.

The IgG antibody test runs on the Architect i1000SR and i2000SR instruments and will expand to the company's Alinity i system.

The reimbursement rates for the most commonly performed SARS-CoV-2 serologic tests are $42.13 and $45.23, depending on the billing code used.

The Abbott test had fewer false positive and false negative results but diagnostic sensitivity in both tests was poor during the first two weeks of symptoms, the study said.

A recent study from New York University found Abbott's ID Now rapid point-of-care test could return false negative results.

The paper, which is not peer-reviewed, said that use of the test as a first-step screening tool would require confirmation of more than 80 percent of its results.